Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/imr.12418

http://scihub22266oqcxt.onion/10.1111/imr.12418
suck pdf from google scholar
C4837659!4837659 !27088907
unlimited free pdf from europmc27088907
    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27088907 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid27088907
      Immunol+Rev 2016 ; 271 (1 ): 56-71
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Thymus: the next (re)generation #MMPMID27088907
  • Chaudhry MS ; Velardi E ; Dudakov JA ; van den Brink MR
  • Immunol Rev 2016[May]; 271 (1 ): 56-71 PMID27088907 show ga
  • As the primary site of T-cell development, the thymus plays a key role in the generation of a strong yet self-tolerant adaptive immune response, essential in the face of the potential threat from pathogens or neoplasia. As the importance of the role of the thymus has grown, so too has the understanding that it is extremely sensitive to both acute and chronic injury. The thymus undergoes rapid degeneration following a range of toxic insults, and also involutes as part of the aging process, albeit at a faster rate than many other tissues. The thymus is, however, capable of regenerating, restoring its function to a degree. Potential mechanisms for this endogenous thymic regeneration include keratinocyte growth factor (KGF) signaling, and a more recently described pathway in which innate lymphoid cells produce interleukin-22 (IL-22) in response to loss of double positive thymocytes and upregulation of IL-23 by dendritic cells. Endogenous repair is unable to fully restore the thymus, particularly in the aged population, and this paves the way toward the need for exogenous strategies to help regenerate or even replace thymic function. Therapies currently in clinical trials include KGF, use of the cytokines IL-7 and IL-22, and hormonal modulation including growth hormone administration and sex steroid inhibition. Further novel strategies are emerging in the preclinical setting, including the use of precursor T cells and thymus bioengineering. The use of such strategies offers hope that for many patients, the next regeneration of their thymus is a step closer.
  • |*Regeneration [MESH]
  • |Adaptive Immunity [MESH]
  • |Aging/*immunology [MESH]
  • |Animals [MESH]
  • |Biological Therapy [MESH]
  • |Clinical Trials as Topic [MESH]
  • |Dendritic Cells/*physiology [MESH]
  • |Fibroblast Growth Factor 7/*metabolism [MESH]
  • |Humans [MESH]
  • |Immunity, Innate [MESH]
  • |Interleukin-22 [MESH]
  • |Interleukin-7/metabolism [MESH]
  • |Interleukins/metabolism [MESH]
  • |Signal Transduction [MESH]
  • |T-Lymphocytes/*physiology [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box